

ORIGINAL ARTICLE

All-cause and cancer-specific mortality in GORD in a population-based cohort study (the HUNT study)

Eivind Ness-Jensen,^{1,2,3} Eivind Gottlieb-Vedi,¹ Karl Wahlin,¹ Jesper Lagergren^{1,4}

¹Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

²HUNT Research Centre, Department of Public Health and General Practice, NTNU, Norwegian University of Science and Technology, Levanger, Norway

³Medical Department, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

⁴Division of Cancer Studies, King's College London, London, UK

Correspondence to

Dr Eivind Ness-Jensen, Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden; eivind.ness-jensen@ki.se

Received 27 June 2016

Revised 5 October 2016

Accepted 9 October 2016

Published Online First

27 October 2016

ABSTRACT

Objective Gastro-oesophageal reflux is a public health concern which could have associated oesophageal complications, including adenocarcinoma, and possibly also head-and-neck and lung cancers. The aim of this study was to test the hypothesis that reflux increases all-cause and cancer-specific mortalities in an unselected cohort.

Design The Nord-Trøndelag health study (HUNT), a Norwegian population-based cohort study, was used to identify individuals with and without reflux in 1995–1997 and 2006–2008, with follow-up until 2014. All-cause mortality and cancer-specific mortality were assessed from the Norwegian Cause of Death Registry and Cancer Registry. Multivariable Cox regression was used to calculate HRs with 95% CIs for mortality with adjustments for potential confounders.

Results We included 4758 participants with severe reflux symptoms and 51 381 participants without reflux symptoms, contributing 60 323 and 747 239 person-years at risk, respectively. Severe reflux was not associated with all-cause mortality, overall cancer-specific mortality or mortality in cancer of the head-and-neck or lung. However, for men with severe reflux a sixfold increase in oesophageal adenocarcinoma-specific mortality was found (HR 6.09, 95% CI 2.33 to 15.93) and the mortality rate was 0.27 per 1000 person-years. For women, the corresponding mortality was not significantly increased (HR 3.68, 95% CI 0.88 to 15.27) and the mortality rate was 0.13 per 1000 person-years.

Conclusions Individuals with severe reflux symptoms do not seem to have increased all-cause mortality or overall cancer-specific mortality. Although the absolute risk is small, individuals with severe reflux symptoms have a clearly increased oesophageal adenocarcinoma-specific mortality.

INTRODUCTION

GORD is a public health concern that affects as many as 10%–30% of the adult population in Western countries and the prevalence is increasing.^{1–2} The main established risk factors for GORD are heredity, obesity and tobacco smoking.^{3–5} GORD is defined by troublesome symptoms of heartburn or regurgitation, and is associated with substantial reductions in health-related quality of life and coincides with several other conditions, including sleep problems, asthma and other respiratory disorders.^{6–9} Complications of GORD include oesophagitis, peptic strictures of the oesophagus, Barrett's oesophagus, and oesophageal and oesophagogastric junctional adenocarcinomas.^{10–11}

Significance of this study**What is already known on this subject?**

- ▶ GORD is defined by troublesome symptoms of heartburn or regurgitation.
- ▶ GORD is frequent in Western populations and the prevalence is increasing.
- ▶ GORD is associated with several complications, including oesophageal adenocarcinoma and possibly cancers of the head-and-neck and lung.

What are the new findings?

- ▶ Severe reflux symptoms were not associated with any increased all-cause mortality, overall cancer-specific mortality or head-and-neck and lung cancer-specific mortalities.
- ▶ Severe reflux symptoms were associated with increased oesophageal adenocarcinoma-specific mortality.
- ▶ As only 14 of 4758 individuals with severe reflux symptoms were diagnosed with oesophageal adenocarcinoma, the absolute risk is low.

How might it impact on clinical practice in the foreseeable future?

- ▶ GORD can be considered a benign disorder with no increased all-cause mortality. However, the clinician should be aware of the clear association with oesophageal adenocarcinoma and oesophageal adenocarcinoma-specific mortality, and rapid endoscopy should be performed if suspected.

Oesophageal and junctional adenocarcinomas are characterised by poor prognosis with a 5-year survival below 20%, increasing incidence and a male predominance.^{12–14} GORD is also associated with some extra-oesophageal cancers, including head-and-neck and lung cancers.^{15–17} Despite the fact that GORD is associated with all these conditions, few studies have examined whether GORD is associated with a reduced overall prognosis or increased risk of cancer-specific mortality. The results from the available literature are conflicting.^{18–20}

As the risk of oesophageal adenocarcinoma is known to be increased in reflux, we expected to find increased mortality from oesophageal adenocarcinoma and, thereby, also increased overall



CrossMark

To cite: Ness-Jensen E, Gottlieb-Vedi E, Wahlin K, et al. *Gut* 2018;**67**:209–215.

Oesophagus

cancer-specific and all-cause mortalities. Due to the association with head-and-neck and lung cancers, we also expected to find increased mortality from these cancers. The aim of this study was to test these hypotheses in a large and unselected cohort of individuals.

METHODS

Design

For the purpose of this study, data from the Norwegian population-based cohort study, the Nord-Trøndelag health study (HUNT), was used. All residents of Nord-Trøndelag county aged 20 years and older were invited to participate in three consecutive health surveys: HUNT1 (1 January 1984 to 28 February 1986), HUNT2 (1 August 1995 to 30 June 1997) and HUNT3 (1 October 2006 to 30 June 2008). In addition, a separate questionnaire was sent to non-participants after HUNT3 in 2009 (questionnaire for non-participants). HUNT includes questionnaires that cover a wide range of health-related information, including reflux symptoms, lifestyle factors and clinical measurements. Data on reflux symptoms were available in HUNT2, HUNT3 and the questionnaire for non-participants. Further information on data collection and design is available elsewhere.²¹ Follow-up started from the initiation of HUNT2 (1 August 1995) until the end of the study (31 December 2014), thus defining the study period. If an individual participated in both HUNT2 and HUNT3 or the questionnaire for non-participants, follow-up started at date of participation in HUNT2.

Follow-up involved linking the HUNT data to the Norwegian Cancer Registry and the Norwegian Cause of Death Registry, using the 11-digit national identity number assigned to each Norwegian resident. All deaths in Norway are registered in the Norwegian Cause of Death Registry, and the Cancer Registry of Norway has a high level of completeness (98.8% in 2001–2005).^{22 23} In addition, HUNT receives updated information on emigration from Statistics Norway every quarter. Participants diagnosed with any cancer before participation in HUNT were excluded.

Exposure

The study exposure was severe reflux symptoms. In HUNT2, HUNT3 and the questionnaire for non-participants, the participants were asked 'to what degree have you had heartburn or acid regurgitation in the last 12 months?' and answered according to three alternatives: 'no', 'minor' or 'severe' complaints. Participants reporting severe complaints were defined as exposed, and those reporting no complaints as unexposed. This definition of severe reflux has been validated with excellent results in a previous study, showing that 95% of participants reporting severe reflux symptoms experience reflux symptoms at least once a week.²⁴ Those reporting minor complaints were not included in this study. Individuals participating in both HUNT2 and HUNT3 or the questionnaire for non-participants and reporting different degrees of reflux symptoms (severe and never) in the different studies were excluded to avoid interchange in the exposure.

Outcomes

The study outcomes were all-cause mortality, overall cancer-specific mortality, oesophageal adenocarcinoma-specific mortality and mortality from head-and-neck or lung cancer.

All-cause mortality

From the Cause of Death Registry, information was gathered on the dates of death among the participants. All deaths among the HUNT participants, that is, independent of cause, were included in the calculations for all-cause mortality.

Overall cancer-specific mortality

From the Cancer Registry, information was gathered on the site of cancer based on the International Classification of Diseases (ICD)-7 codes, morphology based on ICD-O-3 codes and date of cancer diagnoses. We defined cancer deaths as deaths reported in the Cause of Death Registry as caused by cancer only for participants who had a cancer diagnosis registered in the Cancer Registry as well. Participants diagnosed with any cancer as the cause of death were included in the calculations for cancer-specific mortality.

Oesophageal adenocarcinoma-specific mortality

Participants with oesophageal adenocarcinoma as the cause of death reported in the Cause of Death Registry, or deaths occurring within 1 year from the cancer diagnosis in the Cancer Registry, regardless of the registered cause of death in the Cause of Death Registry, were included in the calculations for oesophageal adenocarcinoma-specific mortality. We also included oesophagogastric junctional adenocarcinomas in this outcome.

Mortality from selected extra-oesophageal cancer sites

The extra-oesophageal cancer sites included cancers of the head and neck (labial, lingual, salivary, oral, pharyngeal, nasosinusoidal, laryngeal cancer) and lung. Participants with any of these selected extra-oesophageal cancers as the cause of death reported in the Cause of Death Registry, or deaths occurring within 1 year of the cancer diagnosis in the Cancer Registry, regardless of registered cause of death in the Cause of Death Registry, were included in the calculations of extra-oesophageal cancer-specific mortality.

Confounders

As potential confounders we selected age, body mass index (BMI), tobacco smoking, alcohol consumption, physical activity, education level, chronic obstructive pulmonary disease, cardiovascular diseases, diabetes and hypertension. Information on these factors was collected through both HUNT2 and HUNT3. Height and weight were objectively measured by trained personnel in HUNT2 and HUNT3.²¹ In the questionnaire for non-participants, height and weight were self-reported. BMI was calculated by dividing weight in kilograms by height in square metres (kg/m^2) and categorised according to the WHO's classification: <18.5 (underweight), 18.5–25 (normal weight), 25–30 (overweight) or >30 (obese).²⁵ The participant's tobacco smoking status was categorised as never, previous or current. Alcohol consumption was assessed by the number of occasions of consumption per month and categorised as less than weekly or at least weekly consumption. Physical activity was assessed by hours or occasions of physical activity per week. High physical activity was defined as at least 1 hour, or at least one occasion, of physical activity per week. In addition, participants who reported high levels of walking at work were categorised into the high physical activity group. Low physical activity was anything lower than these cut-offs for high activity. Educational level was categorised as 12 years and less or more than 12 years of formal education. The presence of comorbidities was based on self-reported questionnaires. Chronic obstructive pulmonary

disease included chronic bronchitis, emphysema and cough with phlegm for periods of at least 3 months. In addition, participants reporting previous or current asthma who also reported previous or current smoking were defined as having chronic obstructive pulmonary disease. Cardiovascular disease included previous myocardial infarction, angina pectoris or stroke/brain haemorrhage. The presence of diabetes was reported by the participants. Those participants reporting previous or current use of medication for high blood pressure were defined as having hypertension.

Statistical analysis

Time at risk was defined from the date of the first participation in HUNT2, HUNT3 or the questionnaire for non-participants until date of death, emigration or the end of the study (31 December 2014), whichever came first. HRs with 95% CIs were calculated using multivariable Cox regression comparing the mortality among individuals reporting severe reflux symptoms

with those reporting no reflux symptoms. All analyses were performed separate for each sex. The HRs were adjusted for age (continuous variable), BMI (<18.5, 18.5–25, 25–30 or >30), tobacco smoking status (never, previously or current), alcohol consumption (<weekly or ≥weekly), physical activity (high or low), education (≤12 years or >12 years), chronic obstructive pulmonary disease (yes or no), cardiovascular diseases (yes or no), diabetes (yes or no) and hypertension (yes or no). In addition, analyses were stratified by age (<40, 40–60 and >60 years) to evaluate effect modification.

Ethical approval

The study has ethical approval through the Regional Committee for Medical and Health Research Ethics, Central Norway (2012/1290 4.2009.328), including additional approval of the present study (approved 02.11.2015). All participants in HUNT gave written informed consent when participating stating that




Figure 1 Flow chart of inclusion and exclusion of individuals considered for participation in this study. *The Nord-Trøndelag Health Study. †Questionnaire for non-participants.

Oesophagus

their data could be used in future medical research, including linkage to other registries.

RESULTS

Study participants

A flowchart showing all exclusions of individuals considered for participation is shown in [figure 1](#). After exclusion of 750 individuals (1.3%) due to different degree of reflux symptoms reported in the different studies, 4758 individuals with severe reflux symptoms and 51 381 without reflux symptoms participated, contributing 60 323 and 747 239 person-years at risk, respectively. The average follow-up was 14.4 years. Baseline characteristics of the study participants are shown in [table 1](#). The participants with reflux were older, had higher BMI, drank alcohol less frequently, were more physically active, less educated and had more comorbidity than those without reflux, while the groups had a more similar distribution of sex and tobacco smoking status ([table 1](#)). In total, 9093 deaths occurred in the study population. The number of deaths for each sex, outcome and reflux status is shown in [table 2](#).

Reflux and all-cause mortality

The crude all-cause mortality was higher in women with reflux (HR 1.61, 95% CI 1.46 to 1.78), but no difference remained after adjustment for the selected confounders (HR 1.05, 95% CI 0.92 to 1.19) ([table 2](#)). Age was the main factor explaining the difference in the crude and adjusted mortality rates in women.

Reflux and overall cancer-specific mortality

The crude cancer-specific mortality of all cancer types was increased in women with reflux (HR 1.49, 95% CI 1.21 to 1.83), but after adjustment for age and other confounders this increase became attenuated and statistically non-significant (HR 1.11, 95% CI 0.87 to 1.42) ([table 2](#)).

Reflux and oesophageal adenocarcinoma-specific mortality

The oesophageal adenocarcinoma-specific mortality was higher among men with reflux than those without. A sixfold difference remained after adjustment for confounders (HR 6.09, 95% CI 2.33 to 15.93). For women with reflux, the crude oesophageal adenocarcinoma-specific mortality was increased (HR 5.67, 95% CI 1.78 to 18.10), but after adjustments the association attenuated and became statistically non-significant (HR 3.68, 95% CI 0.88 to 15.27) ([table 2](#)). No participants with severe reflux symptoms died of oesophageal squamous cell carcinoma, compared with 17 participants without reflux symptoms.

Reflux and mortality from head-and-neck and lung cancers

The head-and-neck and lung cancer-specific mortality was not associated with reflux ([table 2](#)).

Reflux and mortality stratified by age

Stratification by age categories did not substantially alter the overall results regarding all-cause mortality or mortality related to cancer in men. In women, reflux became associated with increased risk of oesophageal adenocarcinoma-specific mortality among the participants above 60 years of age (HR 10.49, 95% CI 1.99 to 55.27) ([table 3](#)).

DISCUSSION

In this study, severe reflux symptoms were not associated with any increase in all-cause mortality, overall cancer-specific

Table 1 Baseline characteristics of the study participants

	Severe reflux n (%)	No reflux n (%)
Total	4758 (100.0)	51 381 (100.0)
Age		
Median years (range)	51.9 (19.3 to 101.1)	44.7 (19.1 to 102.1)
Sex		
Males	2301 (48.4)	23 699 (46.1)
Females	2457 (51.6)	27 682 (53.9)
Body mass index		
<18.5	14 (0.3)	454 (0.1)
18.5 to 25	998 (21.0)	22 761 (44.3)
25 to 30	2245 (47.2)	20 558 (40.0)
>30	1453 (30.5)	7052 (13.7)
Missing	48 (1.0)	556 (1.1)
Tobacco smoking status		
Never	1579 (33.2)	23 725 (46.2)
Previous	1648 (34.6)	12 861 (25.0)
Current	1447 (30.4)	14 027 (27.3)
Missing	84 (1.8)	768 (1.5)
Alcohol consumption		
<Weekly	2944 (61.9)	29 423 (57.3)
≥Weekly	1814 (38.1)	21 958 (42.7)
Physical activity		
High	2381 (50.0)	23 017 (44.8)
Low	2123 (44.6)	26 532 (51.6)
Missing	254 (5.3)	1832 (3.6)
Education		
≤12 years	3297 (69.3)	31 640 (61.6)
>12 years	479 (10.1)	9563 (18.6)
Missing	982 (20.6)	10 178 (19.8)
Chronic obstructive pulmonary disease		
Yes	270 (5.7)	966 (1.9)
No	4380 (92.1)	48 504 (94.4)
Missing	108 (2.3)	1911 (3.7)
Cardiovascular disease		
Yes	547 (11.5)	2950 (5.7)
No	4150 (87.2)	46 685 (90.9)
Missing	61 (1.3)	1746 (3.4)
Diabetes		
Yes	193 (4.1)	1450 (2.8)
No	4547 (95.6)	49 806 (96.9)
Missing	18 (0.4)	125 (0.2)
Hypertension		
Yes	1030 (21.6)	5971 (11.6)
No	3668 (77.1)	43 659 (85.0)
Missing	60 (1.3)	1751 (3.4)

mortality or head-and-neck and lung cancer-specific mortality, but only an increase in oesophageal adenocarcinoma-specific mortality.

Strengths of this study include its prospective and population-based design, which counteracts recall bias and selection bias. The population of Nord-Trøndelag County is representative of the Norwegian population as a whole,²⁶ and therefore the results can be generalised to other Western populations. The data on reflux have been well validated against a more comprehensive assessment with excellent results.²⁴ Cancer deaths were retrieved both from the Cancer Registry and the Cause of Death Registry to validate these data. The population studied was large

Table 2 Number of deaths, mortality rates and HRs with 95% CIs for all-cause, cancer-specific, oesophageal adenocarcinoma-specific, and head-and-neck and lung cancer-specific mortality among participants reporting severe and no reflux symptoms, stratified by sex

Outcome	Number of deaths		Mortality rates (per 1000 person-years)		Mortality rate ratio (95% CI)	HR (95% CI)		
	Severe reflux	No reflux	Severe reflux	No reflux		Crude	Age adjusted	Fully adjusted*
Men								
All-cause mortality	397	4459	13.55	13.06	1.04 (0.93 to 1.15)	1.07 (0.99 to 1.19)	0.97 (0.87 to 1.07)	0.95 (0.84 to 1.07)
Overall cancer-specific mortality	108	1200	3.68	3.51	1.05 (0.85 to 1.28)	1.09 (0.89 to 1.32)	0.99 (0.81 to 1.21)	1.08 (0.87 to 1.34)
Oesophageal adenocarcinoma-specific mortality	8	17	0.27	0.05	5.48 (2.05 to 13.4)	5.45 (2.35 to 12.66)	4.89 (2.10 to 11.39)	6.09 (2.33 to 15.93)
Head-and-neck and lung cancer-specific mortality	31	303	1.06	0.89	1.19 (0.80 to 1.73)	1.24 (0.85 to 1.79)	1.13 (0.78 to 1.64)	1.09 (0.71 to 1.67)
Women								
All-cause mortality	430	3807	13.86	9.38	1.48 (1.33 to 1.63)	1.61 (1.46 to 1.78)	1.05 (0.95 to 1.16)	1.05 (0.92 to 1.19)
Overall cancer-specific mortality	98	943	3.16	2.32	1.36 (1.09 to 1.68)	1.49 (1.21 to 1.83)	1.07 (0.87 to 1.32)	1.11 (0.87 to 1.42)
Oesophageal adenocarcinoma-specific mortality	4	10	0.13	0.02	5.23 (1.20 to 18.14)	5.67 (1.78 to 18.10)	3.92 (1.22 to 12.61)	3.68 (0.88 to 15.27)
Head-and-neck and lung cancer-specific mortality	17	189	0.55	0.47	1.18 (0.67 to 1.93)	1.29 (0.78 to 2.11)	0.96 (0.59 to 1.59)	1.21 (0.68 to 2.16)

*Adjusted for age, body mass index, tobacco smoking, alcohol consumption, physical activity, education, chronic obstructive pulmonary disease, cardiovascular diseases, diabetes and hypertension.

Table 3 HRs with 95% CIs for all-cause mortality, overall cancer-specific mortality, oesophageal adenocarcinoma-specific mortality, and head-and-neck and lung cancer-specific mortality among participants reporting severe and no reflux symptoms, stratified by sex and age categories

Outcome	<40 years			40–60 years			>60 years		
	Number of deaths		HR (CI 95%)*	Number of deaths		HR (CI 95%)*	Number of deaths		HR (CI 95%)*
	Severe reflux	No reflux		Severe reflux	No reflux		Severe reflux	No reflux	
Men									
All-cause mortality	7	118	0.95 (0.43 to 2.09)	96	778	1.02 (0.81 to 1.29)	294	3563	0.86 (0.74 to 0.99)
Overall cancer-specific mortality	2	28	1.08 (0.24 to 4.81)	35	314	1.09 (0.76 to 1.58)	71	858	1.02 (0.77 to 1.34)
Oesophageal adenocarcinoma-specific mortality	0	0	–	4	3	81.73 (8.50 to 785.53)	4	14	3.59 (0.98 to 13.20)
Head-and-neck and lung cancer-specific mortality	0	4	–	11	98	0.81 (0.40 to 1.64)	20	201	1.27 (0.74 to 2.18)
Women									
All-cause mortality	5	96	1.36 (0.54 to 3.45)	52	589	1.02 (0.74 to 1.40)	373	3122	0.93 (0.81 to 1.07)
Overall cancer-specific mortality	1	52	0.55 (0.07 to 4.04)	22	326	0.77 (0.48 to 1.24)	75	565	1.24 (0.92 to 1.66)
Oesophageal adenocarcinoma-specific mortality	0	0	–	0	4	–	4	6	10.49 (1.99 to 55.27)
Head-and-neck and lung cancer-specific mortality	0	5	–	5	84	0.80 (0.32 to 2.01)	12	100	1.32 (0.63 to 2.77)

*Adjusted for body mass index, tobacco smoking, alcohol consumption, physical activity, education, chronic obstructive pulmonary disease, cardiovascular diseases, diabetes and hypertension.

and the time of follow-up was long, providing a robust statistical power.

Limitations include possible information bias, as most of the confounders adjusted for in this study came from self-reported questionnaires.^{27 28}

In this study, we excluded the individuals reporting minor reflux symptoms. We believe that these individuals are a heterogeneous group, most without true reflux disease. This statement is based on two validation studies performed on the questionnaire used in the HUNT study. In these validation studies, we found that 95%–98% of the participants reporting *severe* reflux symptoms also reported at least weekly reflux symptoms, while only 25%–31% of the participants reporting *minor* reflux

symptoms also reported at least weekly reflux symptoms.^{1 24} At least weekly reflux is considered the cut-off level for defining reflux disease according to the Montreal definition.⁶ We believe that the group of individuals reporting minor reflux symptoms mostly include individuals with physiological reflux or functional complaints and not individuals with true reflux disease. Thus, by excluding these, we are confident that the validity of the study is increased.

In the analyses, we dichotomised three of the covariables with large number of categories in the questionnaires, that is, alcohol consumption, physical activity and education, using common and previously used cut-off levels decided beforehand. This was done to maintain statistical power and to make the variables

correspond well due to slight revisions of the questionnaires between the studies. We also did a sensitivity analyses with more categories of the covariables in the model, and the results remained virtually unchanged (data not shown).

The study has low rates of missing values among the participants (<5%), except for education (20%). As education was assessed in HUNT2 only, we have missing information on education among those participants only participating in HUNT3 or the questionnaire for non-participants. In Cox regression analyses, only 'complete cases' are analysed and participants with missing information are excluded. To assess the effect of missing data on education, we ran a sensitivity analysis using data from HUNT2 participants only. In this sensitivity analysis, missing for education was reduced to only 3.6%. However, the sensitivity analysis did not change the results (data not shown), meaning that the missing values did not affect the conclusion of the study.

The number of individuals (n=750) excluded from the analyses due to change in reported complaints with reflux disease between HUNT2 and HUNT3 or the questionnaire for non-participants was small (1.3%) compared with the total number of included participants (n=56 139) and should not have major influence on the results.

As mortality was the main outcome of this study, we excluded participants with a cancer diagnosis in the Cancer Registry, but without this cancer reported as the cause of death in the Cause of Death Registry. However, for oesophageal adenocarcinoma and head-and-neck and lung cancers we did still include these participants if they died within 1 year after the date of cancer diagnosis, as we believe that these deaths still could be related to these cancers as they are known to have a poor prognosis. This decision could overestimate the cancer-specific mortality of the respective cancers, but still reflux was not associated with head-and-neck and lung cancer-specific mortality.

The results of this study align with those from a smaller population-based cohort study from the USA, which found no difference in all-cause mortality between 115 individuals with daily and 2708 individuals without reflux symptoms.¹⁸ A cohort study from the UK found that patients with GORD (n=7159) had a 60% increased all-cause mortality within the first year of follow-up after inclusion, compared with patients without GORD (n=10 000), but no difference was seen for the remaining 4 years of follow-up.¹⁹ In our study, reflux was neither associated with all-cause mortality after 1 nor 5 years of follow-up (data not shown). Interpreting the results from the present study and the findings of previous studies indicate that reflux does not affect overall all-cause mortality.

The findings regarding cancer-specific mortality are different from an Iranian population-based cohort study reporting that participants with severe reflux symptoms (n=172) had a 48% increase in cancer-specific mortality compared with participants without reflux symptoms (n=1240), while no association was found for oesophageal cancer.²⁰ However, the Iranian study could not separate oesophageal adenocarcinoma from squamous cell carcinoma, and most oesophageal cancers in Iran are squamous cell carcinomas without any association with reflux.¹⁰ Moreover, differences in study design, living conditions and ethnicity, as well as chance, may explain the divergent findings.

Our study confirms the lack of association between reflux and oesophageal squamous cell carcinomas as there were no deaths due to oesophageal squamous cell carcinoma among the participants with severe reflux symptoms, while there were 17 deaths due to oesophageal squamous cell carcinoma among those without reflux symptoms. Reflux was also, as expected, not

associated with gastric (non-cardia) cancer-specific mortality (data not shown).

The increased oesophageal adenocarcinoma-related mortality is expected, given the well established and strong association between GORD and oesophageal adenocarcinoma incidence.^{10 12} Yet, only 14 of the 4758 individuals with severe reflux symptoms were diagnosed with an oesophageal adenocarcinoma, which emphasises the fact that the absolute risk is low even in individuals with GORD.²⁹ This is, to the best of our knowledge, the first study examining the mortality related to head-and-neck and lung cancers, and no association was found.

In conclusion, this prospective and population-based cohort study with a large sample size and adjustment for confounding factors indicates that severe reflux symptoms do not entail any increased all-cause mortality or overall cancer-specific mortality, although an increase in oesophageal adenocarcinoma-specific mortality was found.

Correction notice This article has been corrected since it published Online First. The results section of the abstract has been updated.

Acknowledgements The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine, NTNU, Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. The study has used data from the Cancer Registry of Norway and the Norwegian Cause of Death Registry. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Cancer Registry of Norway or the Norwegian Cause of Death Registry is intended nor should be inferred.

Contributors EN-J contributed to the study concept and design, statistical analyses and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, approved the final version of the manuscript and is guarantor for the overall content of the manuscript. EG-V contributed to the study concept and design, statistical analyses and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. KW contributed to the statistical analysis and interpretation of data, critical revision of the manuscript for important intellectual content and approved the final version of the manuscript. JL contributed to the study concept and design, critical revision of the manuscript for important intellectual content and approved the final version of the manuscript.

Funding EN-J, KW and JL are funded by the Swedish Research Council.

Competing interests None declared.

Ethics approval The Regional Committee for Medical and Health Research Ethics, Central Norway.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Ness-Jensen E, Lindam A, Lagergren J, *et al.* Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. *Gut* 2012;61:1390–7.
- 2 El-Serag HB, Sweet S, Winchester CC, *et al.* Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut* 2014;63:871–80.
- 3 Cameron AJ, Lagergren J, Henriksson C, *et al.* Gastroesophageal reflux disease in monozygotic and dizygotic twins. *Gastroenterology* 2002;122:55–9.
- 4 Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Ann Intern Med* 2005;143:199–211.
- 5 Hallan A, Bomme M, Hveem K, *et al.* Risk factors on the development of new-onset gastroesophageal reflux symptoms. a population-based prospective cohort study: The HUNT Study. *Am J Gastroenterol* 2015;110:393–400; quiz 401.
- 6 Vakil N, van Zanten SV, Kahrilas P, *et al.* The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900–20; quiz 43.
- 7 Kulig M, Leodolter A, Vieth M, *et al.* Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease—an analysis based on the ProGERD initiative. *Aliment Pharmacol Ther* 2003;18:767–76.
- 8 Lindam A, Ness-Jensen E, Jansson C, *et al.* Gastroesophageal reflux and sleep disturbances: a bidirectional association in a population-based cohort study, The HUNT Study. *Sleep* 2016;39:1421–7.

- 9 Gislasen T, Janson C, Vermeire P, *et al.* Respiratory symptoms and nocturnal gastroesophageal reflux: a population-based study of young adults in three European countries. *Chest* 2002;121:158–63.
- 10 Lagergren J, Bergström R, Lindgren A, *et al.* Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999;340:825–31.
- 11 Rubenstein JH, Scheiman JM, Sadeghi S, *et al.* Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. *Am J Gastroenterol* 2011;106:254–60.
- 12 Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. *Gastroenterology* 2015;149:302–17.e1.
- 13 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- 14 Xie SH, Lagergren J. The Male Predominance in Esophageal Adenocarcinoma. *Clin Gastroenterol Hepatol* 2016;14:338–47.e1.
- 15 Langevin SM, Michaud DS, Marsit CJ, *et al.* Gastric reflux is an independent risk factor for laryngopharyngeal carcinoma. *Cancer Epidem Biomar* 2013;22:1061–8.
- 16 Vaezi MF, Qadeer MA, Lopez R, *et al.* Laryngeal cancer and gastroesophageal reflux disease: a case-control study. *Am J Med* 2006;119:768–76.
- 17 Bacciu A, Mercante G, Ingegnoli A, *et al.* Effects of gastroesophageal reflux disease in laryngeal carcinoma. *Clin Otolaryngol Allied Sci* 2004;29:545–8.
- 18 Talley NJ, Locke GR III, McNally M, *et al.* Impact of gastroesophageal reflux on survival in the community. *Am J Gastroenterol* 2008;103:12–19.
- 19 Ruigómez A, García Rodríguez LA, Wallander MA, *et al.* Natural history of gastro-oesophageal reflux disease diagnosed in general practice. *Aliment Pharmacol Ther* 2004;20:751–60.
- 20 Islami F, Pourshams A, Nasseri-Moghaddam S, *et al.* Gastroesophageal reflux disease and overall and cause-specific mortality: a prospective study of 50000 individuals. *Middle East J Dig Dis* 2014;6:65–80.
- 21 Krokstad S, Langhammer A, Hveem K, *et al.* Cohort profile: the HUNT Study, Norway. *Int J Epidemiol* 2013;42:968–77.
- 22 Norwegian Institute of Public Health. Cause of Death Registry. Secondary Cause of Death Registry. 26 May 2015. http://www.fhi.no/eway/default.aspx?pid=240&trg=MainContent_6898&Main_6664=6898:0:25,7524:1:0:0:::0:0&MainContent_6898=6706:0:25,9002:1:0:0:::0:0
- 23 Larsen IK, Småstuen M, Johannesen TB, *et al.* Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness. *Eur J Cancer* 2009;45:1218–31.
- 24 Nilsson M, Johnsen R, Ye W, *et al.* Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. *JAMA* 2003;290:66–72.
- 25 WHO. *Obesity: preventing and managing the global epidemic. Report of a WHO consultation.* World Health Organization, 2000: 9.
- 26 Statistical Yearbook of Norway. *Oslo-Konsvinger.* Norway: Statistics Norway, 2011.
- 27 Huerta JM, José Tormo M, Egea-Caparrós JM, *et al.* Accuracy of self-reported diabetes, hypertension and hyperlipidemia in the adult Spanish population. DINO study findings. *Rev Esp Cardiol* 2009;62:143–52.
- 28 Newell SA, Girgis A, Sanson-Fisher RW, *et al.* The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. *Am J Prev Med* 1999;17:211–29.
- 29 Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. *Gastroenterol Clin North Am* 2015;44:203–31.



All-cause and cancer-specific mortality in GORD in a population-based cohort study (the HUNT study)

Eivind Ness-Jensen, Eivind Gottlieb-Vedi, Karl Wahlin and Jesper Lagergren

Gut 2018 67: 209-215 originally published online October 27, 2016
doi: 10.1136/gutjnl-2016-312514

Updated information and services can be found at:
<http://gut.bmj.com/content/67/2/209>

These include:

References

This article cites 26 articles, 2 of which you can access for free at:
<http://gut.bmj.com/content/67/2/209#ref-list-1>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Gastro-oesophageal reflux](#) (351)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>